Drug intelligence / Profile preview

OTP-01

Development stage: Phase 2
Lead developer: Ottimo Pharma
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

OTP-01 is a lead drug candidate developed by Ottimo Pharma, a private biotech company co-founded by Medicxi and Jonny Finlay. The company, which emerged from stealth in October 2024 after securing capital from investors including Medicxi, OrbiMed, and Avoro Capital, is focused on advancing a pipeline of dual-pathway antibodies for cancer. OTP-01 is part of this pipeline, indicating its intended use as an antineoplastic agent targeting cancer through a dual-pathway mechanism.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on OTP-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTP-01.

Explore the full profile